You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 118 No. 9, September 2000 TABLE OF CONTENTS
  Archives
  •  Online Features
  Clinical Sciences
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (8)
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in this journal
 Topic Collections
 •Immunology
 •Immunologic Disorders
 •Alert me on articles by topic

Risk Factors for Advancement of Cytomegalovirus Retinitis in Patients With Acquired Immunodeficiency Syndrome

Janet T. Holbrook, PhD, MPH; Matthew D. Davis, MD; Larry D. Hubbard, MA; Barbara K. Martin, PhD; Gary N. Holland, MD; Douglas A. Jabs, MD, MS; Adele Kaplan Gilpin, PhD, JD; Curtis Meinert, PhD; Daniel S. Reshef, MD, MPH, PhD; for the Studies of Ocular Complications of AIDS Research Group

Arch Ophthalmol. 2000;118:1196-1204.

Objective  To identify ocular and systemic factors that predict advancement of cytomegalovirus (CMV) retinitis during treatment.

Methods  Patients with acquired immunodeficiency syndrome were enrolled in a multicenter clinical trial designed to evaluate foscarnet sodium and ganciclovir sodium as therapy for newly diagnosed CMV retinitis. Ocular characteristics at baseline and measurements of retinitis were assessed from fundus photographs by graders at a fundus photograph reading center. The following measures of advancement were assessed: (1) lesion border movement of at least 750 µm or development of a new lesion in involved eyes; (2) rate of increase in retinal area with CMV in involved eyes; and (3) development of retinitis in uninvolved eyes of patients with unilateral disease at baseline.

Results  In eyes with retinitis, risk factors at baseline for advancement while receiving treatment included smaller area involved, active margins of retinitis, and posterior location. Risk factors for development of retinitis in uninvolved fellow eyes included blood and urine cultures positive for CMV and lower CD8+ T-lymphocyte count.

Conclusions  Lesion characteristics can be used to predict advancement of preexisting disease, whereas only systemic factors are associated with development of bilateral disease. These analyses describe retinitis activity before the introduction of potent antiretroviral therapies but provide an important reference point for patients in whom CMV retinitis develops after failure or intolerance of antiretroviral agents.


From the Center for Clincal Trials, Department of Epidemiology (Drs Holbrook, Martin, Gilpin, Meinert, and Reshef), and the Departments of Ophthalmology and Medicine (Dr Jabs), The Johns Hopkins University School of Medicine, Baltimore, Md; the Fundus Photograph Reading Center, University of Wisconsin, Madison (Dr Davis and Mr Hubbard); and the University of California–Los Angeles Ocular Inflammatory Disease Center, Jules Stein Institute and Department of Ophthalmology, University of California–Los Angeles School of Medicine (Dr Holland). A complete list of participants in the Studies of Ocular Complications of AIDS was published previously (Arch Ophthalmol. 1996;114:804).


RELATED ARTICLE

Archives of Ophthalmology Reader's Choice: Continuing Medical Education
Arch Ophthalmol. 2000;118(9):1310-1311.
FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Photographic Measures of Cytomegalovirus Retinitis as Surrogates for Visual Outcomes in Treated Patients
Holbrook et al.
Arch Ophthalmol 2001;119:554-563.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2000 American Medical Association. All Rights Reserved.